- Conditions
- Hypertension
- Interventions
- CIN-107
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021
- U.S. locations
- 2
- States / cities
- Orlando, Florida • Tampa, Florida
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 121–144
of 9,283
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Relapsed/Refractory Multiple Myeloma
- Interventions
- Dose Escalation, MEDI2228, ADC (antibody drug conjugate), Dose Expansion, MEDI2228, ADC (antibody drug conjugate)
- Biological
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 18 Years to 101 Years
- Enrollment
- 107 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 8
- States / cities
- Phoenix, Arizona • Jacksonville, Florida • Boston, Massachusetts + 4 more
- Conditions
- Advanced Malignant Solid Tumor, Solid Tumor Cancer
- Interventions
- PLT012
- Drug
- Lead sponsor
- Pilatus Biosciences Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Dallas, Texas • Houston, Texas
- Conditions
- Cough
- Interventions
- GSK5464714- Camlipixant
- Drug
- Lead sponsor
- Bellus Health Inc. - a GSK company
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- EGFR Inhibitor-associated Rash
- Interventions
- ATR04-484, Vehicle
- Drug
- Lead sponsor
- Azitra Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 6
- States / cities
- Hot Springs, Arkansas • New Haven, Connecticut • New York, New York + 3 more
- Conditions
- Relapsed or Refractory Multiple Myeloma
- Interventions
- mRNA-2808
- Drug
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 190 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • San Francisco, California • Atlanta, Georgia + 6 more
- Conditions
- Healthy
- Interventions
- PF-04965842, Probenecid
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Advanced Solid Tumor, Lymphoma
- Interventions
- DS-3078a
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Healthy Volunteers, Chemical Terrorism, Chemical Warfare
- Interventions
- Human Butyrylcholinesterase (HuBChE) derived from human plasma, Placebo: Normal saline
- Drug
- Lead sponsor
- Baxalta now part of Shire
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- Lenexa, Kansas
- Conditions
- Wilson Disease
- Interventions
- UX701, Standard of Care (SOC)
- Genetic · Drug
- Lead sponsor
- Ultragenyx Pharmaceutical Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 82 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2034
- U.S. locations
- 12
- States / cities
- Los Angeles, California • Redwood City, California • Sacramento, California + 9 more
- Conditions
- Hepatic Impairment (HI)
- Interventions
- EDG-7500
- Drug
- Lead sponsor
- Edgewise Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026
- U.S. locations
- 2
- States / cities
- Miami, Florida • Orlando, Florida
- Conditions
- Healthy Volunteers
- Interventions
- Vonoprazan
- Drug
- Lead sponsor
- Phathom Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation
- Interventions
- JDQ443
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 95 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Providence, Rhode Island
- Conditions
- Recurrent Osteosarcoma, Refractory Osteosarcoma
- Interventions
- Docetaxel, Gemcitabine, Hydroxychloroquine
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Leukemia, Lymphoma
- Interventions
- rituximab, fludarabine phosphate, pixantrone dimaleate
- Biological · Drug
- Lead sponsor
- CTI BioPharma
- Industry
- Eligibility
- 18 Years to 120 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2007
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Colon Cancer, Metastatic Colon Cancer
- Interventions
- ST316, FOLFIRI regimen & bevacizumab, Fruquintinib, Lonsurf & bevacizumab
- Drug
- Lead sponsor
- Sapience Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 11
- States / cities
- Birmingham, Alabama • Los Angeles, California • Denver, Colorado + 8 more
- Conditions
- B-cell Lymphomas (Phase 1), Advanced Solid Tumors (Phase 1), Diffuse Large B-cell Lymphoma (Phase 2), Follicular Lymphoma (Phase 2), Transformed Follicular Lymphoma, Primary Mediastinal Large B-Cell Lymphoma
- Interventions
- Tazemetostat, Prednisolone
- Drug
- Lead sponsor
- Epizyme, Inc.
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2021
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • Duarte, California • Santa Barbara, California + 9 more
- Conditions
- Male Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
- Interventions
- oblimersen sodium, doxorubicin hydrochloride, docetaxel, filgrastim, pegfilgrastim, therapeutic conventional surgery, pharmacological study, laboratory biomarker analysis
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2008
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- laromustine
- Drug
- Lead sponsor
- Vion Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2004
- U.S. locations
- 3
- States / cities
- Tucson, Arizona • New Haven, Connecticut • West Haven, Connecticut
- Conditions
- Stargardt Disease, Stargardt Macular Degeneration, Stargardt Macular Dystrophy
- Interventions
- SB-007
- Genetic
- Lead sponsor
- Splice Bio
- Industry
- Eligibility
- 12 Years to 65 Years
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 5
- States / cities
- Aurora, Colorado • Miami, Florida • Boston, Massachusetts + 2 more
- Conditions
- Healthy Volunteers
- Interventions
- GEH200520 Injection and GEH200521 (18F) Injection, Static - PET/CT scan
- Drug · Diagnostic Test
- Lead sponsor
- GE Healthcare
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Acute Leukemia of Ambiguous Lineage
- Interventions
- Revumenib, Venetoclax, Azacitidine, intrathecal (IT) chemotherapy, Cytarabine, Methotrexate
- Drug
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- 1 Year to 30 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 10
- States / cities
- San Diego, California • Aurora, Colorado • Atlanta, Georgia + 7 more
- Conditions
- Healthy Volunteers
- Interventions
- ACP-196, Omeprazole
- Drug
- Lead sponsor
- Acerta Pharma BV
- Industry
- Eligibility
- 19 Years to 65 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016
- U.S. locations
- 1
- States / cities
- Lincoln, Nebraska
- Conditions
- Malaria, Prevention and Control, Acquired Immunity
- Interventions
- PfSPZ
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland